111 related articles for article (PubMed ID: 8701030)
21. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo.
Scarpignato C; Kisfalvi I; D'Amato M; Varga G
Aliment Pharmacol Ther; 1996 Jun; 10(3):411-9. PubMed ID: 8791971
[TBL] [Abstract][Full Text] [Related]
22. PD-135,158, a cholecystokinin(B) antagonist, enhances latent inhibition in the rat.
Gracey DJ; Bell R; King DJ
Pharmacol Biochem Behav; 2000 Mar; 65(3):459-63. PubMed ID: 10683486
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog.
Fossa AA; DePasquale MJ; Morrone J; Zorn SH; Bryce D; Lowe JA; McLean S
J Pharmacol Exp Ther; 1997 Apr; 281(1):180-7. PubMed ID: 9103496
[TBL] [Abstract][Full Text] [Related]
24. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers.
McCann UD; Slate SO; Geraci M; Uhde TW
Anxiety; 1994-1995; 1(6):258-67. PubMed ID: 9160584
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and receptor binding affinity of cholecystokinin receptor ligands: 2-and 1-indolyl derivatives of PD134308.
Araldi G; Donati D; Oliosi B; Ursini A; van Amsterdam F; Natalini B; Pellicciari R; Tarzia G
Farmaco; 1996 Jul; 51(7):471-6. PubMed ID: 8765669
[TBL] [Abstract][Full Text] [Related]
26. Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260.
Lines C; Challenor J; Traub M
Br J Clin Pharmacol; 1995 Mar; 39(3):235-42. PubMed ID: 7619662
[TBL] [Abstract][Full Text] [Related]
27. Cholecystokinin-B receptor ligands of the dipeptoid series act as agonists on rat stomach histidine decarboxylase.
Ding XQ; Chen D; Håkanson R
Gastroenterology; 1995 Oct; 109(4):1181-7. PubMed ID: 7557084
[TBL] [Abstract][Full Text] [Related]
28. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder.
Pande AC; Greiner M; Adams JB; Lydiard RB; Pierce MW
Biol Psychiatry; 1999 Sep; 46(6):860-2. PubMed ID: 10494457
[TBL] [Abstract][Full Text] [Related]
29. Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats.
Honore P; Buritova J; Fournié-Zaluski MC; Roques BP; Besson JM
J Pharmacol Exp Ther; 1997 Apr; 281(1):208-17. PubMed ID: 9103499
[TBL] [Abstract][Full Text] [Related]
30. The effects of intrathecally administered FK480, a cholecystokinin-A receptor antagonist, and YM022, a cholecystokinin-B receptor antagonist, on the formalin test in the rat.
Yamamoto T; Nozaki-Taguchi N
Anesth Analg; 1996 Jul; 83(1):107-13. PubMed ID: 8659718
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.
Coudoré-Civiale MA; Méen M; Fournié-Zaluski MC; Boucher M; Roques BP; Eschalier A
Br J Pharmacol; 2001 May; 133(1):179-85. PubMed ID: 11325808
[TBL] [Abstract][Full Text] [Related]
32. The effect of CCKB/gastrin antagonists on stimulated gastric acid secretion in the anaesthetized rat.
Hayward NJ; Harding M; Lloyd SA; McKnight AT; Hughes J; Woodruff GN
Br J Pharmacol; 1991 Dec; 104(4):973-7. PubMed ID: 1687371
[TBL] [Abstract][Full Text] [Related]
33. Peripheral axotomy influences the in vivo release of cholecystokinin in the spinal cord dorsal horn-possible involvement of cholecystokinin-B receptors.
Gustafsson H; de Araújo Lucas G; Schött E; Stiller CO; Alster P; Wiesenfeld-Hallin Z; Brodin E
Brain Res; 1998 Apr; 790(1-2):141-50. PubMed ID: 9593865
[TBL] [Abstract][Full Text] [Related]
34. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.
Abelson JL; Nesse RM
Biol Psychiatry; 1994 Jul; 36(2):73-83. PubMed ID: 7948449
[TBL] [Abstract][Full Text] [Related]
35. Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones.
Beinborn M; Chen C; DeMeo L; McBride EW; Kopin AS
Yale J Biol Med; 1998; 71(3-4):337-46. PubMed ID: 10461364
[TBL] [Abstract][Full Text] [Related]
36. The CCK-B receptor antagonist Cl 988 reverses tolerance to morphine in rats.
Hoffmann O; Wiesenfeld-Hallin Z
Neuroreport; 1994 Dec; 5(18):2565-8. PubMed ID: 7696605
[TBL] [Abstract][Full Text] [Related]
37. Pentagastrin-induced protein synthesis in the parotid gland of the anaesthetized rat, and its dependence on CCK-A and -B receptors and nitric oxide generation.
Cevik Aras H; Ekström J
Exp Physiol; 2006 Jul; 91(4):673-9. PubMed ID: 16556659
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the effects of PD 134308 (CI-988), a CCK-B antagonist, on the punished responding of squirrel monkeys.
Powell KR; Barrett JE
Neuropeptides; 1991 Jul; 19 Suppl():75-8. PubMed ID: 1679212
[TBL] [Abstract][Full Text] [Related]
39. Cholecystokinin and panic disorder: past and future clinical research strategies.
Bradwejn J; Koszycki D
Scand J Clin Lab Invest Suppl; 2001; 234():19-27. PubMed ID: 11713976
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and pharmacological properties of ureidomethylcarbamoylphenylketone derivatives. A new potent and subtype-selective nonpeptide CCK-B/gastrin receptor antagonist, S-0509.
Hagishita S; Murakami Y; Seno K; Kamata S; Haga N; Konoike T; Kanda Y; Kiyama R; Shiota T; Ishihara Y; Ishikawa M; Shimamura M; Abe K; Yoshimura K
Bioorg Med Chem; 1997 Aug; 5(8):1695-714. PubMed ID: 9313871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
